Humacyte (NASDAQ:HUMA) Sees Large Volume Increase

Humacyte, Inc. (NASDAQ:HUMA) shares saw unusually-high trading volume on Tuesday . Approximately 638,996 shares changed hands during trading, a decline of 64% from the previous session’s volume of 1,775,598 shares.The stock last traded at $5.32 and had previously closed at $5.37.

Wall Street Analyst Weigh In

HUMA has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a report on Tuesday. Benchmark reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Tuesday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Humacyte in a research note on Tuesday, March 26th.

Humacyte Stock Performance

The stock has a 50 day moving average price of $5.92 and a two-hundred day moving average price of $4.20. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. The company has a market capitalization of $628.74 million, a price-to-earnings ratio of -5.40 and a beta of 1.52.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). On average, analysts predict that Humacyte, Inc. will post -0.95 EPS for the current fiscal year.

Insider Activity

In other news, Director Brady W. Dougan sold 271,518 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the transaction, the director now owns 4,559,140 shares of the company’s stock, valued at $33,281,722. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 271,518 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the completion of the sale, the director now directly owns 4,559,140 shares of the company’s stock, valued at approximately $33,281,722. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gordon M. Binder bought 50,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were acquired at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the transaction, the director now owns 160,000 shares in the company, valued at approximately $1,084,800. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 54,412 shares of company stock valued at $369,107 and sold 1,628,820 shares valued at $12,464,121. Insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. acquired a new position in shares of Humacyte in the 4th quarter valued at $29,000. China Universal Asset Management Co. Ltd. increased its holdings in Humacyte by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after purchasing an additional 9,325 shares during the last quarter. SG Americas Securities LLC lifted its stake in Humacyte by 52.8% in the fourth quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after buying an additional 5,645 shares during the period. Powell Investment Advisors LLC boosted its holdings in Humacyte by 75.0% during the fourth quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock worth $60,000 after buying an additional 9,000 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. acquired a new position in shares of Humacyte during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.